Gita Ramjee1,2,3, Reshmi Dassaye1, Tarylee Reddy4, Handan Wand5. 1. HIV Prevention Research Unit, South African Medical Research Council, KwaZulu-Natal, South Africa. 2. Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, United Kingdom. 3. Department of Global Health, School of Medicine, University of Washington, Seattle. 4. Biostatistics Unit, South African Medical Research Council, Durban, KwaZulu-Natal, South Africa. 5. The Kirby Institute, University of New South Wales, Kensington, Australia.
Abstract
Background: Women enrolled in human immunodeficiency virus (HIV) prevention efficacy trials receive counseling on prevention of HIV, sexually transmitted infections (STIs), and pregnancy during every visit. Incident pregnancy has an impact on efficacy outcomes. Incidence rates of pregnancy and HIV/STIs among women who became pregnant and associated risk factors were assessed. Methods: Data from 9165 women participating in HIV prevention trials in KwaZulu-Natal, South Africa from 2002-2012 were combined. Demographic and behavioral predictors of incidence pregnancy and incidence HIV and STIs were determined using Cox regression models. Results: Overall pregnancy incidence was 9.6 per 100 person-year (py) (95% confidence interval [Cl], 9.1-10.3). Human immunodeficiency virus incidence among pregnant women was 5.93 per 100 py (95% Cl, 4.73-7.44). Incidence of STIs among pregnant women for Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, and Treponema pallidum (syphilis) were 10.87, 7.42, 3.92, and 1.43 per 100 py, respectively. In the adjusted analyses, we observed overlapping risk factors for HIV acquisition during pregnancy, ie, young age, not married/not cohabitating, and low parity. The risk of pregnancy and HIV acquisition is more than 3 times higher among young women (<20 years of age). Conclusions: We identified overlapping risk factors for pregnancy and HIV incidence, suggesting an urgent need for appropriate, targeted, individual-centred counseling for women participating in HIV prevention trials.
Background: Women enrolled in human immunodeficiency virus (HIV) prevention efficacy trials receive counseling on prevention of HIV, sexually transmitted infections (STIs), and pregnancy during every visit. Incident pregnancy has an impact on efficacy outcomes. Incidence rates of pregnancy and HIV/STIs among women who became pregnant and associated risk factors were assessed. Methods: Data from 9165 women participating in HIV prevention trials in KwaZulu-Natal, South Africa from 2002-2012 were combined. Demographic and behavioral predictors of incidence pregnancy and incidence HIV and STIs were determined using Cox regression models. Results: Overall pregnancy incidence was 9.6 per 100 person-year (py) (95% confidence interval [Cl], 9.1-10.3). Human immunodeficiency virus incidence among pregnant women was 5.93 per 100 py (95% Cl, 4.73-7.44). Incidence of STIs among pregnant women for Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, and Treponema pallidum (syphilis) were 10.87, 7.42, 3.92, and 1.43 per 100 py, respectively. In the adjusted analyses, we observed overlapping risk factors for HIV acquisition during pregnancy, ie, young age, not married/not cohabitating, and low parity. The risk of pregnancy and HIV acquisition is more than 3 times higher among young women (<20 years of age). Conclusions: We identified overlapping risk factors for pregnancy and HIV incidence, suggesting an urgent need for appropriate, targeted, individual-centred counseling for women participating in HIV prevention trials.
Authors: Lindi Masson; Jo-Ann S Passmore; Lenine J Liebenberg; Lise Werner; Cheryl Baxter; Kelly B Arnold; Carolyn Williamson; Francesca Little; Leila E Mansoor; Vivek Naranbhai; Douglas A Lauffenburger; Katharina Ronacher; Gerhard Walzl; Nigel J Garrett; Brent L Williams; Mara Couto-Rodriguez; Mady Hornig; W Ian Lipkin; Anneke Grobler; Quarraisha Abdool Karim; Salim S Abdool Karim Journal: Clin Infect Dis Date: 2015-04-21 Impact factor: 9.079
Authors: Koleka Mlisana; Nivashnee Naicker; Lise Werner; Lindi Roberts; Francois van Loggerenberg; Cheryl Baxter; Jo-Ann S Passmore; Anneke C Grobler; A Willem Sturm; Carolyn Williamson; Katharina Ronacher; Gerhard Walzl; Salim S Abdool Karim Journal: J Infect Dis Date: 2012-04-19 Impact factor: 5.226
Authors: Thomas L Patterson; Shirley J Semple; Hugo Staines; Remedios Lozada; Prisci Orozovich; Jesus Bucardo; Morgan M Philbin; Minya Pu; Miguel Fraga; Hortensia Amaro; Adela de la Torre; Gustavo Martinez; Carlos Magis-Rodríguez; Steffanie A Strathdee Journal: J Infect Dis Date: 2008-03-01 Impact factor: 5.226
Authors: Hendrée E Jones; Felicia A Browne; Bronwyn J Myers; Tara Carney; Rachel Middlesteadt Ellerson; Tracy L Kline; Winona Poulton; William A Zule; Wendee M Wechsberg Journal: Int J Pediatr Date: 2011-04-06
Authors: Maria A Keating; Gloria Hamela; William C Miller; Agnes Moses; Irving F Hoffman; Mina C Hosseinipour Journal: PLoS One Date: 2012-06-29 Impact factor: 3.240